Skip to content
Peptide Atlas
All peptides

Thymalin

Tier 3 · Reported use
Also known as Thymus peptide complex · Thymalinum

The strongest evidence present is Tier 1: a large observational cohort of 266 elderly persons over 6-8 years (variously described as observational and, by one vendor, as a single adequately-powered RCT, PMID 14523363) plus tier-1 reviews and psoriasis/endometrial clinical studies. However, most human data are observational rather than blinded RCTs, nearly all research originates from a single Russian group (Khavinson laboratory) with limited independent Western replication, and pharmacokinetic and specific mortality-percentage figures come only from tier-3 vendor material. Thymalin is an undefined, batch-variable bovine thymus extract with a theoretical prion/contamination risk and no FDA/EMA approval.

Half-life
~7 h
Routes
Intramuscular injection · Subcutaneous injection · Parenteral (lyophilized injectable)
Goals
immune support · longevity
Cost / mg
Not recorded

How it works

Sources describe Thymalin as a polypeptide complex isolated from the thymus gland of young calves that acts as an immune regulator. Khavinson-group sources report it contains short peptides (the dipeptides EW and KE and the tripeptide EDP) that are said to bind DNA and histone proteins to influence which genes are switched on, thereby helping bone-marrow-derived precursor cells mature into T-lymphocytes and restoring balance to the immune system. Sources report it dampens pro-inflammatory signaling and enhances the activity of immune cells such as natural killer cells and phagocytes. Because it is a mixture rather than a single defined molecule, one vendor characterizes its effects as broader but less targeted than single-sequence peptides(vendor claim).

Overview

Overview

Sources report that Thymalin (also called Thymus peptide complex or Thymalinum) is a polypeptide complex isolated from the thymus gland of young calves (bovine calf thymus)3,4. Vendor sources report it was developed in the 1970s in the Soviet Union by Vladimir Khavinson and Vyacheslav Morozov at the Military Medical Academy in Leningrad, with a tier-2 study noting Khavinson characterized these peptides from 1973 onwards11. Sources give varying regulatory dates: one states first USSR approval in 1982 for immunodeficiency states, others say Russia since the 1980s or 1970s; Khavinson-group studies and a vendor cite a Russian registration number LS-000267 dated February 26, 20103,4.

A tier-1 review describes Thymalin as a polypeptide drug used for diseases associated with immune dysfunction, viral and bacterial infections, normalization of regeneration, immunodepression, and depression of hematopoiesis following chemical and radiotherapy1.

Composition and classification

Multiple Khavinson-group sources report Thymalin's components include the dipeptide EW (thymogen), the dipeptide KE, and the tripeptide EDP1,3,4,16. A vendor reports the EW dipeptide has molecular formula C16H19N3O5 and molecular weight 333.34 g/mol(vendor claim). Multiple vendor sources describe Thymalin's molecular weight as roughly 1,000-10,000 Da\of of short peptides of 2-8 amino acids(vendor claim). Khavinson-group sources state manufacturing uses special extraction and purification that completely degrades macromolecular proteins while preserving peptides under 10 kDa2; a vendor reports it is produced by acid hydrolysis of bovine calf thymus tissue followed by ultrafiltration to isolate peptides below 10 kDa. A vendor classes Thymalin among the cytomedin family of short peptide bioregulators that influence DNA transcription and cellular differentiation(vendor claim).

Reported mechanism

Khavinson-group studies report that the short peptides KE, EW and EDP can specifically bind double-stranded DNA and/or histone proteins to regulate gene expression, immune-protein synthesis, gerontogene activity and stem-cell differentiation3,4. A tier-2 docking study reports GGAG as the preferred DNA sequence for EW and GCGC for KE, and identified AKT1/AKT2 as potential target genes involved in cytokine-storm development10. In vitro, Thymalin and its EW and KE dipeptides reduced IL-1beta, IL-6 and TNF-alpha synthesis in human PBMCs by 1.4-6.0 times10, and a THP-1 monocyte study reported inhibition of LPS-stimulated TNF and IL-6 and induction of TNF tolerance11. Khavinson-group and tier-2 reports describe modulation of hematopoietic stem cell markers (CD44, CD117 down; CD28 up) interpreted as stimulating differentiation into mature T-lymphocytes3,4,12. A tier-1 review states the immunoprotective effect is expressed as restoration of T and B lymphocytes and their subpopulations, increased functional activity and increased phagocytosis1. One vendor theorizes its polypeptide composition produces broader but less targeted effects than single-sequence peptides12.

Reported clinical and preclinical evidence

A tier-1 study reports that in 266 elderly and older persons observed over 6-8 years, Thymalin and Epithalamin improved indices of the cardiovascular, endocrine, immune and nervous systems, homeostasis and metabolism2,5,6. The same dataset reports Thymalin alone produced a 2.0-2.1-fold decrease in mortality versus control, Epithalamin alone a 1.6-1.8-fold decrease, the combination a 2.5-fold decrease, and the combination applied annually for 6 years a 4.1-fold decrease2,5,6. It is worth noting these primary sources describe the study as observational, while one vendor characterizes it as a single adequately-powered RCT (PMID 14523363)(vendor claim). Separately, a tier-3 vendor characterizes the trial as producing a 45% reduction in cardiovascular mortality and a 28% reduction in all-cause mortality ,'s figures that appear only on that single site(vendor claim). Tier-1 studies also report Thymalin was associated with a 2.0-2.4-fold decrease in acute respiratory disease incidence and reduced incidence of ischemic heart disease, hypertension, deforming osteoarthrosis and osteoporosis1,2,5,6.

Khavinson-group studies report that in COVID-19, Thymalin plus standard therapy (n=36) produced more rapid clinical improvement than standard therapy alone (n=44), with faster recovery from lymphopenia and normalization of C-reactive protein, D-dimer, lymphocyte and NK-cell counts, and that it halved hospital mortality in older patients with severe COVID-193,4,16. A case report describes a 2-fold increase in lymphocytes, 7-fold in eosinophils, and reductions of 8x in CRP, 2.5x in IL-6 and 7.2x in D-dimer3,4. A tier-2 study describes efficacy in acute respiratory distress syndrome and COPD and in complex therapy of severe COVID-1910,12. Khavinson-group sources report use in hepatitis A and B, erysipelas, meningococcal infection, typhoid fever, pneumonia and cavernous pulmonary tuberculosis3,4.

Additional tier-1 clinical reports include a study of 104 psoriasis patients showing decreased T-helper/T-suppressor ratios versus control, and 27 psoriatics treated with Thymalinum plus Natrii nucleinas whose ratio rose from 1.0 to 1.74 with shorter rash regression and prolonged remissions8, and use of Thymalinum with norcolut and myelopidum in 55 patients with hyperplastic endometrial processes7. Animal studies (mice, rats, Drosophila, 1971-2001) are reported to prolong lifespan and inhibit age-related disorders2, with a vendor citing 20-30% lifespan extension in animal models. Tier-2 animal studies report a pronounced antitumor effect against transplanted sarcoma 45 in rats13 and activation of reparative osteogenesis around a jaw bone defect in WAG rats9. Tier-3/4 sources describe potential roles in correcting radiative immunodeficiencies20, dental and maxillofacial pathology17, and athlete recovery and anti-aging protocols22.

Evidence caveats

A vendor profile characterizes the overall evidence base as roughly 73% preclinical and 27% clinical, with an Evidence Score of 57/100, noting most studies come from a single Russian group (the Khavinson laboratory) with limited Western replication; another vendor counts 234 published studies and notes Thymalin is approved in Russia but never evaluated by Western regulators and is an undefined bovine thymus extract with batch-consistency challenges(vendor claim). Readers should note that nearly all evidence originates from one research group, most human data are observational rather than blinded RCTs, and sources disagree on whether Thymalin is a natural extract or synthetic and on its approval dates.

What the research shows

153 findings extracted from the 22 sources cited below, strongest evidence first within each group. Every one links to the source it came from.

What human studies found

Based on 54 human study findings, 6 animal findings, 1 in vitro finding, 4 expert opinion findings and 1 theoretical finding.

  • human studyThymalin normalizes the functions of the immune system and stimulates regeneration and hematopoiesis if suppressed1

  • human studyUse of thymalin reduced incidence of acute respiratory diseases in elderly and senile people1

  • human studyThymalin treatment in patients with acute lung abscesses led to decrease in systemic inflammatory response syndrome, decrease in plasma fibrinolytic activity, and cessation of hypercoagulation1

  • human studyThymalin has shown geroprotective properties in animal experiments and clinical studies1

  • human studyThymalin contributed to restoration of immune system functions and reduced mortality in elderly patients1

  • human studyThymalin and Epithalamin normalized basic functions of the human organism, improving indices of cardiovascular, endocrine, immune and nervous systems, homeostasis and metabolism in 266 elderly and older persons during 6-8 years2

  • human studyThymalin treatment resulted in 2.0-2.1-fold decrease in mortality rate compared to control2

  • human studyThymalin plus Epithalamin combination resulted in 2.5-fold decrease in mortality rate compared to control2

Show 58 more findings

  • human studyThymalin in combination with Epithalamin applied annually for 6 years resulted in 4.1-fold decrease in mortality rate compared to control2

  • human studyThymalin treatment associated with 2.0-2.4-fold decrease in acute respiratory disease incidence2

  • human studyThymalin treatment reduced incidence of ischemic heart disease, hypertension disease, deforming osteoarthrosis and osteoporosis2

  • human studyPatients administered Thymalin with standard therapy manifested more rapid clinical improvement compared to standard therapy only3

  • human studyThymalin produced higher proportions of recovery from lymphopenia3

  • human studyThymalin produced faster normalization of C-reactive protein, D-dimer, lymphocyte and NK-cell counts3

  • human studyThymalin halved hospital mortality in older patients with severe COVID-193

  • human studyAdministration of Thymalin reduced the incidence of acute respiratory infections in senior patients 2.0-2.4-fold3

  • human studyThymalin reduced mortality in senior patients over a 6-year observation period3

  • human studyIn severe COVID-19 case, Thymalin increased blood lymphocytes 2-fold3

  • human studyIn severe COVID-19 case, Thymalin increased eosinophils 7-fold3

  • human studyIn severe COVID-19 case, Thymalin reduced C-reactive protein 8 times3

  • human studyIn severe COVID-19 case, Thymalin reduced IL-6 2.5 times3

  • human studyIn severe COVID-19 case, Thymalin reduced D-dimer 7.2 times3

  • human studyThymalin is effective in case of various infectious diseases including hepatitis A and B, erysipelas, meningococcal infection, typhoid fever4

  • human studyThymalin is effective in acute respiratory diseases, pneumonia of various origins, cavernous pulmonary tuberculosis4

  • human studyAdministration of Thymalin reduced the incidence of acute respiratory infections in senior patients 2.0–2.4-fold4

  • human studyThymalin reduced mortality in senior patients over a 6-year observation period4

  • human studyPatients administered with Thymalin against the background of standard therapy (n=36) manifested more rapid clinical improvement compared to standard therapy only (n=44)4

  • human studyThymalin produced higher proportions of recovery from lymphopenia compared to standard therapy alone4

  • human studyThymalin produced faster normalization of C-reactive protein, D-dimer, number of lymphocytes and NK-cells in the blood compared to standard therapy alone4

  • human studyThymalin halved hospital mortality in older patients with severe COVID-194

  • human studyIn a case study, combination of Thymalin and comprehensive treatment increased blood lymphocyte concentration 2-fold and eosinophils 7-fold4

  • human studyIn a case study, Thymalin combination therapy reduced C-reactive protein, IL-6, and D-dimer concentration by 8, 2.5 and 7.2 times respectively4

  • human studyThymalin improved cardiovascular system indices in 266 elderly and older persons over 6-8 years5

  • human studyThymalin improved endocrine system indices in elderly and older persons5

  • human studyThymalin improved immune system indices in elderly and older persons5

  • human studyThymalin improved nervous system indices in elderly and older persons5

  • human studyThymalin restored homeostasis and improved metabolism in elderly and older persons5

  • human studyThymalin treatment resulted in 2.0-2.4-fold decrease in acute respiratory disease incidence compared to control5

  • human studyThymalin treatment reduced incidence of ischemic heart disease clinical manifestations compared to control5

  • human studyThymalin treatment reduced incidence of hypertension disease compared to control5

  • human studyThymalin treatment reduced incidence of deforming osteoarthrosis compared to control5

  • human studyThymalin treatment reduced incidence of osteoporosis compared to control5

  • human studyThymalin-treated group showed 2.0-2.1-fold decreased mortality rate during observation period compared to control5

  • human studyThymalin in combination with Epithalamin treated annually for 6 years resulted in 4.1-fold decreased mortality rate compared to control5

  • human studyThymalin and Epithalamin improved indices of the cardiovascular, endocrine, immune, and nervous systems, homeostasis, and metabolism in elderly and older persons6

  • human studyThymalin treatment resulted in 2.0-2.4-fold decrease in acute respiratory disease incidence compared to control group6

  • human studyThymalin treatment reduced incidence of ischemic heart disease clinical manifestations, hypertension, deforming osteoarthrosis, and osteoporosis compared to control group6

  • human studyThymalin-treated patients showed 2.0-2.1-fold decrease in mortality rate during observation period compared to control group6

  • human studyThymalin combined with Epithalamin showed 2.5-fold decrease in mortality compared to control group6

  • human studyThymalin combined with Epithalamin applied annually for 6 years resulted in 4.1-fold mortality decrease compared to control level6

  • human studyThe combined treatment scheme of norcolut with immune modulators thymalinum and myelopidum increased treatment effectiveness for hyperplastic endometrial processes7

  • human studyThymalinum received in addition to antipsoriatic therapy resulted in an increase in T-helper/T-suppressor ratio and was followed by a favorable clinical course (shorter periods of skin rash regression, prolonged remissions)8

  • human studyThymalin is an immunomodulatory drug containing a polypeptide extract of thymus that has demonstrated efficacy in the therapy of acute respiratory distress syndrome and chronic obstructive pulmonary disease, as well as in complex therapy related to severe COVID-19 in middle-aged and elderly patients10

  • human studyClinical trials of Thymalin have been conducted15

  • animalAnimal studies on mice, rats and Drosophila melanogaster demonstrated that Thymalin significantly prolonged life span and inhibited age-related disorders2

  • animalThymalin injection in soft tissues surrounding a bone defect in the lower jaw, filled with hydroxyapatite-containing osteotropic material (bone graft 'Biomin GT'), activates reparative osteogenesis9

  • animalPronounced antitumor effect of Thymalin in doses lower than the therapeutic doses was shown in experiments on albino outbred male rats with transplanted sarcoma 4513

  • animalTumor growth arrest and its regression were observed in more than half of animals13

  • animalIn other cases, growth was suppressed by 78%13

  • animalTumor regression was accompanied by the development of stable antistress adaptation reactions of calm and elevated activation13

  • in vitroIn vitro model of an inflammatory reaction demonstrated that Thymalin and EW and KE dipeptides reduced the synthesis of IL-1β, IL-6, and TNF-α cytokines in human peripheral blood mononuclear cells by 1.4-6.0 times10

  • expert opinionThymalin appeared to halve hospital mortality rates in older patients with severe COVID-1916

  • expert opinionThymalin is useful in complex treatment of dental diseases in the elderly17

  • expert opinionPineal peptides (Epithalamin, Epitalon) had more effective geroprotective effect on thymus involution compared with geroprotective effect of thymic peptides (Thymalin, Thymogen) on involution of pineal gland18

  • expert opinionPineal peptides (epithalamin, epitalon) had more effective geroprotective effect on thymus involution in comparison with geroprotective effect of thymic peptides (thymalin, thymogen) on involution of pineal gland19

  • theoreticalThymalin is effective in therapy of acute respiratory syndrome, chronic obstructive bronchitis, and other immunopathology12

How it works

Based on 12 human study findings, 10 animal findings, 19 in vitro findings, 12 expert opinion findings and 8 theoretical findings.

  • human studyImmunoprotective effect of thymalin is expressed in restoration of T and B lymphocytes and their subpopulations, increase in functional activity, and increased phagocytosis1

  • human studyThe molecular mechanism of Thymalin immunoprotective action is due to short peptides KE, EW, EDP in its composition3

  • human studyShort peptides can specifically bind to double-stranded DNA and/or histone proteins and regulate gene expression3

  • human studyThymalin regulates synthesis of immune system proteins and activity of gerontogenes3

  • human studyThymalin stimulates stem cell differentiation3

  • human studyThymalin prevents cytokine storm by reducing pro-inflammatory cytokines IL-1α, IL-6, IL-8, TNF-α3

  • human studyThymalin reduces intensity of intravascular blood coagulation in hypercoagulability syndrome3

  • human studyThymalin is accumulated in epithelial cells of the human respiratory tract during early embryogenesis4

Show 53 more findings

  • human studyThymalin prevents the cytokine storm which develops during COVID-19, reducing the concentration of pro-inflammatory cytokines IL-1α, IL-6, IL-8, TNF-α in the blood4

  • human studyThymalin reduces the intensity of intravascular blood coagulation in the development of hypercoagulability syndrome4

  • human studyThymalinum is an immune modulator7

  • human studyIn all forms of psoriasis with a slight alteration in T-lymphocyte content a significant dysbalance of T-helpers and T-suppressors was found that brought about a decrease in the correlation ratio T-helpers/T-suppressors8

  • animalThymalin stimulates reparative osteogenesis by rapid cleaning of bone defect cavity from necrotic tissues and hematoma fragments9

  • animalThymalin injection decreases the number of neutrophil leukocytes in the bone defect area9

  • animalThymalin injection increases the number and morphofunctional state of monocytes, macrophages, and lymphocytes9

  • animalThymalin injection increases the number and morphofunctional state of cells of fibroblastic differon9

  • animalThymalin injection produces balanced change in number and morphofunctional state of osteoblasts and osteoclasts depending on stage of reparative osteogenesis9

  • animalThymalin injection activates hematopoietic processes in lamellar bone tissue from the regenerate9

  • animalThymalin injection activates bone tissue mineralization processes9

  • animalSignificant increase in lymphoproliferative activity and the content of tissue basophils and plasmocytes in the thymus lobules was observed13

  • animalThymalin stimulates immunity15

  • animalThymalin's ability to stimulate immunity is associated with anticarcinogenic and geroprotector activities15

  • in vitroIn study on human hematopoietic blood stem cells, Thymalin decreased CD44 expression 2.8-fold3

  • in vitroShort peptides in Thymalin can specifically bind to double-stranded DNA and/or histone proteins and regulate gene expression, synthesis of immune system proteins, activity of gerontogenes, and stimulate stem cell differentiation4

  • in vitroIn a study on human hematopoietic blood stem cells, Thymalin decreased the expression of CD44 on HSC 2.8-fold4

  • in vitroIn a study on human hematopoietic blood stem cells, Thymalin reduced the expression of CD117 on HSC 2.2-fold4

  • in vitroIn a study on human hematopoietic blood stem cells, Thymalin reduced the expression of CD28 on HSC 6.9-fold4

  • in vitroKE stimulates cellular immunity and nonspecific resistance in organisms, exerting an activating effect on macrophages, blood lymphocytes, thymocytes, and neutrophils10

  • in vitroUsing molecular docking, GGAG was found to be the best dsDNA sequence in the classical B-form for binding the EW dipeptide, while GCGC is the preferred dsDNA sequence in the curved nucleosomal form for the KE dipeptide10

  • in vitroCluster analysis revealed that potential target genes for the EW and KE peptides encode the AKT1 and AKT2 proteins involved in the development of the cytokine storm10

  • in vitroThymalin peptide complex can modulate key proliferative patterns, increasing tyrosine phosphorylation of mitogen-activated cytoplasmic kinases in human monocytic THP-1 cells11

  • in vitroThymalin peptide complex inhibits the expression of TNF and pro-inflammatory IL-6 cytokine stimulated by LPS on terminally differentiated THP-1 cells11

  • in vitroThymalin peptide complex reduces cell adhesion in THP-1 cells incubated on a layer of activated endothelial cells (HUVECs activated by LPS)11

  • in vitroThymalin peptide complex acts as a natural inducer of TNF tolerance in monocytes and as an anti-inflammatory molecule during inflammatory and microbial-mediated activity11

  • in vitroThymalin reduced the expression of CD44 (stem cell marker) by 2-3 times12

  • in vitroThymalin reduced the expression of CD117 (molecule of the intermediate stage of HSC differentiation) by 2-3 times12

  • in vitroThymalin increased the expression of CD28 (marker of mature T lymphocytes) by 6.8 times12

  • in vitroThymalin stimulated differentiation of CD117 cells into mature CD28 T lymphocytes12

  • in vitroThymalin could modify radiation-induced cytogenetic effects in peripheral blood lymphocytes of healthy individuals14

  • in vitroThymalin exerts protective or sensitizing action dependent on its concentration, cell radiosensitivity, dose of irradiation, and relative biologic effectiveness of ionizing radiation14

  • in vitroA dipeptide specific for the thymus stimulates in vitro outgrowth of thymus explants15

  • expert opinionThymalin components include EW dipeptide (thymogen), dipeptide KE, and tripeptide EDP1

  • expert opinionShort peptides regulate gene expression and synthesis of heat-shock protein, cytokines, fibrinolysis, gerontogenes, and differentiation, proliferation, apoptosis of cells1

  • expert opinionThymalin is obtained from thymic peptides isolated according to special technology to correct disorders from age-related thymic involution2

  • expert opinionThe molecular mechanism of the Thymalin immunoprotective action is due to the effects of the short peptides KE, EW, EDP in its composition4

  • expert opinionThymalin, a peptide derived from the thymus gland, can play a vital role in modulating the immune response, which is often dysregulated in severe COVID-19 cases, leading to a 'cytokine storm'16

  • expert opinionThe mechanism behind Thymalin's effectiveness in COVID-19 likely stems from its ability to regulate gene expression and immune protein synthesis16

  • expert opinionThe peptides within Thymalin, such as EW, KE, and EDP, are thought to interact with DNA and histones, influencing the production of cytokines and regulating immune cell differentiation16

  • expert opinionThymalin's effects on normalizing the immune status indicators correlate with its known immunoprotective and geroprotective properties16

  • expert opinionThymalin is a natural or synthetic peptide thymomimetic with immunopharmacological effects17

  • expert opinionKey mechanisms of pineal peptides effect on thymus dystrophy is immunoendocrine cooperation, which is realized as transcription's activation of various proteins18

  • expert opinionThe key mechanisms of pineal peptides effect on thymus dystrophy is immunoendocrine cooperation, which is realized as transcription's activation of various proteins19

  • expert opinionIonizing radiation upon the human organism is accompanied by the formation of the secondary radiative immunodeficiencies, which can be treated with immunomodulating preparations20

  • theoreticalKE and EW dipeptides are active substances of Thymalin10

  • theoreticalEW reduces angiotensin-induced vasoconstriction and preserves endothelium-dependent vascular relaxation by inhibiting ACE2, the target protein of SARS-CoV-210

  • theoreticalThe immunomodulatory effect of Thymalin under the inflammatory response conditions in COVID-19 is based on the potential ability of its active components, EW and KE dipeptides, to regulate protein synthesis involved in the development of the cytokine storm10

  • theoreticalThymalin is a polypeptide complex isolated from the thymus and regulating the functions of the immune system12

  • theoreticalThymalin increases functional activity of T lymphocytes12

  • theoreticalThymalin is a synthetic peptide bioregulator that originates from the thymus gland22

  • theoreticalThymalin peptide mechanism of action involves stimulating the thymus gland, leading to increased production and maturation of T-lymphocytes22

  • theoreticalBy influencing gene expression, Thymalin supports cellular repair and regeneration, counteracting age-related cellular damage22

Dosing

Based on 1 animal finding.

  • animalHigh efficiency of Thymalin can be attributed to the use of lower doses of the substance and their modulation during the treatment course in accordance with the regimes of activation therapy13

How the body handles it

Based on 2 human study findings and 1 expert opinion finding.

  • human studyThymalin accumulates in epithelial cells of human respiratory tract during early embryogenesis1

  • human studyThymalin is accumulated in epithelial cells of human respiratory tract during early embryogenesis3

  • expert opinionManufacturing of Thymalin uses special extraction and purification methods resulting in complete degradation of macromolecular proteins while preserving peptides with molecular weight under 10 kDa2

Safety and side effects

Based on 1 human study finding.

  • human studyThymalin and thymogen have practically no side effects1

What people use it for

Based on 7 human study findings, 7 expert opinion findings and 4 theoretical findings.

  • human studyThymalin is a polypeptide drug used for diseases associated with immune dysfunction, viral and bacterial infections, regeneration normalization, immunodepression, and depression of hematopoiesis after chemical and radiotherapy1

  • human studyRegulation of immunogenesis prevents development of cytokine storm in severe COVID-193

  • human studyThymalin is effective in various infectious diseases including hepatitis A and B, erysipelas, meningococcal infection, typhoid fever3

  • human studyThymalin is indicated for health maintenance and age-related pathology prevention in persons over 60 years old6

  • human studyThymalinum combined with norcolut and myelopidum was used to treat 55 patients with hyperplastic endometrial processes7

  • human studyThymalinum was used as an immunomodulator for psoriasis treatment8

  • human studyIn patients with severe COVID-19, the number of CD28, CD4, CD8 T lymphocytes in the blood decreased12

  • expert opinionThymalin is indicated for health maintenance and age-related pathology prevention in persons over 605

Show 10 more findings

  • expert opinionOlder individuals are more susceptible to severe COVID-19 due to age-related thymic involution, making Thymalin a potentially valuable therapeutic strategy16

  • expert opinionThymalin can be used in the protective functions of the body in various dental diseases and pathology of organs and tissues of the maxillofacial region17

  • expert opinionThymalin has geroprotective effect on involution of pineal gland18

  • expert opinionThymalin is a thymic peptide with geroprotective effect on involution of pineal gland19

  • expert opinionPeptide preparations of thymos and bone marrow, referred to the cytomedinum class (thymalinum, thymogenum, haemalinum) were most perspective for the correction of the secondary radiative immunodeficiencies20

  • expert opinionThymalinum can be used in the treatment of radioactive affections of immune system20

  • theoreticalThymalin can be considered as an immunoprotective peptide drug for the prevention of COVID-1912

  • theoreticalThymalin is particularly valuable for individuals with compromised immune systems or those seeking to bolster their defenses against infections22

  • theoreticalThymalin is a sought-after peptide for anti-aging protocols22

  • theoreticalFor athletes and active individuals, Thymalin can be a valuable tool for enhancing recovery and maintaining peak immune function, especially during periods of intense training22

Other findings

Based on 1 human study finding and 2 expert opinion findings.

  • human studyThymalin is isolated from the calve thymus3

  • expert opinionThymalin is a medicinal drug based on a polypeptide complex isolated from the calve thymus4

  • expert opinionThymalin is one of the Khavinson Peptides, characterized by Prof. Khavinson from 1973 onwards, initially isolated from animal tissues and found to be organ specific11

Points of contention

Where the evidence is unsettled, thin, or says less than the popular claim — worth knowing before you draw conclusions.

Single source

Almost all evidence comes from one Russian research group.

Multiple sources note that the overwhelming majority of Thymalin research originates from Vladimir Khavinson's laboratory and affiliated institutions, with limited independent replication by Western laboratories. One vendor states the effect rests on a single adequately-powered Russian RCT (n=266, PMID 14523363).

Limited evidence

Most human clinical data are observational, not blinded RCTs.

The large 266-person, 6–8 year dataset is repeatedly reported as observational; the COVID-19 comparison (n=36 vs n=44) and dramatic case-report figures (2-fold lymphocytes, 8-fold CRP reduction, etc.) are small and non-randomized. A vendor labels the n=266 study a 'single adequately-powered RCT', while the primary sources describe it as an observational study.

Other

Thymalin is an undefined, batch-variable bovine extract, not a single defined compound.

Vendor sources warn that Thymalin is an undefined mixture of peptides from calf thymus whose composition varies between batches, that the exact active peptide responsible for effects is not definitively identified, and that a theoretical prion/contamination risk exists for animal-derived tissue products.

Contested

Sources disagree on whether Thymalin is natural extract or synthetic.

Most sources describe Thymalin as a polypeptide complex extracted from calf thymus, but a tier-4 article calls it a 'synthetic peptide bioregulator' and another describes it as 'natural or synthetic'.

Contested

Approval/development dates vary across sources.

Sources variously state Thymalin was first approved in the USSR in 1982, in Russia since the 1980s, or since the 1970s; development is dated to the 1970s but one tier-2 study notes characterization from 1973 onwards. The registration number LS-000267 is dated February 26, 2010.

Single source

Half-life and pharmacokinetic figures come only from tier-3 vendor pages.

The 6–8 hour half-life, 30–60 minute peak, comparison to thymosin alpha-1 (2–3 hours), and 'weeks-long' detectability claims appear only in tier-3 vendor material (realpeptides.co, paragonsportsmedicine.com), with no primary pharmacokinetic study cited among the higher-tier sources.

Single source

The 45%/28% mortality figures appear only on one vendor site.

The specific 45% cardiovascular and 28% all-cause mortality reduction figures are reported only by a tier-3 vendor (thymalin-peptide.com), whereas the tier-1 primary studies express mortality effects as 2.0–2.1-fold (Thymalin) up to 4.1-fold (combined annual) reductions.

Other

CD28 fold-change reported slightly differently across sources.

The in vitro increase in CD28 (mature T-lymphocyte marker) is reported as 6.9-fold in one Khavinson source and 6.8-fold in the tier-2 study and vendor summary; CD44/CD117 reductions are given as 2.8-/2.2-fold in one place and '2–3 times' in another.

Using it with other compounds

Check a stack
  • Thymosin Alpha-1Same mechanism

    Worth caution

    Both are thymus-derived immune-restoration peptides that normalize T-lymphocyte subsets, boost NK activity, and dampen pro-inflammatory cytokines. Because they push the same immune levers (thymic T-cell maturation and cytokine balancing), running them together is largely redundant rather than additive — pick one thymic immunomodulator rather than layering them.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation

  • ThymulinSame mechanism

    Worth caution

    Both are thymus-derived immune regulators that drive T-lymphocyte precursor maturation, normalize CD4/CD8 balance, boost NK activity, and dampen NF-kB-driven pro-inflammatory cytokines (IL-1, IL-6, TNF-alpha). Thymulin is essentially one of the discrete thymic hormones whose activity Thymalin (a thymic peptide complex) is meant to restore. Running both together is largely redundant rather than additive — pick one thymic immunomodulator and dose it properly rather than layering two overlapping thymic signals.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · T cell regulation · NF kB modulation

  • VilonSame mechanism

    Worth caution

    Vilon is a Khavinson-school peptide bioregulator that, like Thymalin, is proposed to act at the gene/DNA level to normalize cellular immunity, improve CD4/CD8 ratios, and suppress IL-1/IL-6/TNF-alpha with geroprotective intent. They share the same cytomedin/bioregulator rationale and immune-normalizing endpoint, making them redundant partners rather than complementary ones.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although Thymalin and Vilon produce overlapping immune effects, they do not share the same molecular mechanism. Thymalin acts through T-cell receptors, thymic peptide binding, histone (H1/H3) and surface-marker modulation (CD28, CD44, CD117), and binds DNA at GGAG/GCGC/TCGA sites, whereas Vilon is described as receptor-independent, acting via chromatin remodeling and DNA binding at GCGC. Their shared cytokine suppression reflects convergent endpoints, not a common pathway.

    Shares innate immune · anti inflammatory · T cell regulation · NF kB modulation

  • PidotimodComplementary

    Worth caution

    Pidotimod reaches the same immune-support goal by a different route — it matures dendritic cells via TLR-2/TLR-7 and pushes Th1 differentiation and immunoglobulin production, whereas Thymalin works through thymic T-cell maturation. Because they enter the immune network at different points (antigen-presenting-cell activation vs. T-cell precursor maturation), they can plausibly complement each other rather than duplicate.

    Tier 4Theoretical — not established

    Shares innate immune · T cell regulation

  • ImunofanSame mechanism

    Worth caution

    Imunofan is built on a thymopoietin fragment and acts as a bidirectional thymic-type immunomodulator — normalizing CD4/CD8 ratios, enhancing phagocytosis/NK activity, and reducing TNF/IL-6. That overlaps heavily with Thymalin's thymic T-cell restoration, so the two are largely doing the same job through the same thymic-hormone logic. Combining them adds little beyond either alone.

    Tier 4Theoretical — not established
    What the research doesn't establish
    Although both peptides normalize T-cell balance, modulate cytokines, and enhance phagocytosis, they do not do so through the same molecular route. Thymalin acts via DNA/histone binding and NF-kB-linked gene regulation, whereas Imunofan signals through thymopoietin membrane receptors, cAMP/PKA, and redox pathways—so their overlapping effects are convergent, not evidence of a shared mechanism.

    Shares innate immune · anti inflammatory · T cell regulation

  • LactoferrinComplementary

    No documented conflict

    Lactoferrin supports innate defense through direct antimicrobial/iron-sequestering and cytokine-calming actions, a different mechanism from Thymalin's thymic T-cell restoration. The two hit host defense from separate angles (mucosal/innate barrier vs. adaptive T-cell compartment) and both temper pro-inflammatory cytokines, so they can reasonably layer for broad immune support.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory

  • ElafinComplementary

    No documented conflict

    Elafin is an innate-immune protease inhibitor that protects tissue and quiets NF-kB-driven inflammation at mucosal surfaces, a distinct mechanism from Thymalin's thymic adaptive-immune restoration. Both converge on lowering NF-kB inflammatory tone through different upstream biology, so they are complementary rather than redundant.

    Tier 4Theoretical — not established

    Shares innate immune · anti inflammatory · NF kB modulation

Safety and side effects

Safety and tolerability

A tier-1 review states that Thymalin and thymogen have practically no side effects1. Multiple vendor sources report an extensive safety record over 40 years of documented clinical use in Russia with minimal reported adverse effects(vendor claim). A vendor protocol reports Thymalin is well-tolerated after 5 days at the starting dose, with occasional slight injection-site redness, warmth or minor swelling that typically resolves within a few hours, and advises daily site rotation(vendor claim); it notes that high-dose corticosteroids may reduce Thymalin's immune-stimulating effects.

Regulatory and quality caveats

Vendor profiles note Thymalin has no FDA, EMA or other Western regulatory approval(vendor claim). Vendor profiles also caution that as an undefined bovine tissue extract, Thymalin's composition varies between batches and carries a theoretical prion/contamination risk(vendor claim). One vendor notes the exact active peptide responsible for effects is not definitively identified(vendor claim). A vendor also states that Thymalin's half-life and polypeptide composition make it unsuitable for acute immune-challenge scenarios requiring rapid onset(vendor claim). One tier-2 in vitro study reports Thymalin could exert either protective or sensitizing action on radiation-induced cytogenetic effects in peripheral blood lymphocytes depending on concentration, cell radiosensitivity, radiation dose and relative biologic effectiveness14, indicating dose- and context-dependent behavior.

Because almost all safety data derive from a single Russian research group and vendor material rather than independent blinded trials, the strength of the "practically no side effects" characterization should be weighed against the limited independent replication noted across sources.

Reconstitution and handling

Dosing

No dose has been established for this compound by any Western regulator. Vendor profiles note Thymalin has no FDA, EMA or other Western regulatory approval, though it is reported to be registered in Russia (registration number LS-000267 dated February 26, 2010, per3,4/one source). The figures below are what sources report , not guidance.

  • A vendor reports that standard dosing in Russian clinical practice is 10 mg intramuscular daily for 10 days per course(vendor claim).
  • A vendor recommends twice-daily subcutaneous injections over a 10-20 day course to maintain consistent plasma levels, and advises dosing by immune endpoints (CD4+ counts, NK activity, antibody titers) rather than by plasma half-life(vendor claim).
  • A tier-2 animal study attributes Thymalin's reported high antitumor efficiency to use of lower-than-therapeutic doses modulated during the treatment course according to activation-therapy regimes13.

Reconstitution and preparation

A vendor states Thymalin is formulated as a lyophilized injectable for parenteral use and is stable refrigerated at 2-8'C in sealed ampoules(vendor claim).

A vendor protocol describes a 5-10 mg dosing tier with the following reconstitution arithmetic(vendor claim):

  • Reconstituting a 10 mg vial with 1 mL sterile water yields a concentration of 10 mg/mL.
  • At that concentration, a 5 mg dose corresponds to 0.5 mL.
  • The same protocol describes a morning injection with daily injection-site rotation, and advises spacing of 2-3 hours if co-injected with Epitalon.

Reported combinations

A vendor states the most studied Thymalin combination is with Epitalon for enhanced longevity/anti-aging effects, and lists zinc, vitamin C, probiotics and antibiotics as safe complementary combinations(vendor claim). Note that the large observational human dataset2,5,6 studied Thymalin alongside Epithalamin rather than as monotherapy for its combined mortality figures.

Sources

Ordered by evidence quality — the strongest first.

  1. BioBRev2104004Khavinson.fm(opens in a new tab)
    Tier 1Web · khavinson.info
  2. Peptide bioregulators prolong human life(opens in a new tab)
    Tier 1Web · khavinson.info
  3. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 ...(opens in a new tab)
    Tier 1Web · pmc.ncbi.nlm.nih.gov
  4. Peptide Drug Thymalin Regulates Immune Status in Severe COVID-19 Older Patients(opens in a new tab)
    Tier 1Web · khavinson.info
  5. Peptides of pineal gland and thymus prolong human life.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2003
  6. [Geroprotective effect of thymalin and epithalamin].(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  7. Norcolut with immune modulators in the complex treatment for hyperplastic uterine processes.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1993
  8. Subpopulations of T lymphocytes in psoriasis patients and their changes during immunotherapy.(opens in a new tab)
    Tier 1PubMed · pubmed.ncbi.nlm.nih.gov · 1987
  9. Reparative osteogenesis in mandible in cases of filling a bone defect with hydroxyapatite-containing osteotropic material and injecting the surrounding soft tissues with thymalin: experimental and morphological study.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2024
  10. The Influence of KE and EW Dipeptides in the Composition of the Thymalin Drug on Gene Expression and Protein Synthesis Involved in the Pathogenesis of COVID-19.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2023
  11. Peptides Regulating Proliferative Activity and Inflammatory Pathways in the Monocyte/Macrophage THP-1 Cell Line.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2022
  12. Thymalin: Activation of Differentiation of Human Hematopoietic Stem Cells.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  13. Effect of Thymalin on the Tumor and Thymus under Conditions of Activation Therapy In Vivo.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2018
  14. Chornobyl catastrophe: cytogenetic effects of low dose ionizing radiation and their modification.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2016
  15. Peptides and Ageing.(opens in a new tab)
    Tier 2PubMed · pubmed.ncbi.nlm.nih.gov · 2002
  16. Thymalin Peptide in COVID-19: Evidence for Immune Support and Recovery(opens in a new tab)
    Tier 3Web · nbinno.com
  17. [Age features of bioregulatory therapy of dental diseases.].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2020
  18. [Characteristics of the pineal gland and thymus relationship in aging].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2011
  19. [Influence of peptides from pineal gland on thymus function at aging].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 2010
  20. [The correction of secondary radiation-induced immunodeficiencies].(opens in a new tab)
    Tier 3PubMed · pubmed.ncbi.nlm.nih.gov · 1991
  21. The Use of Thymalin for Immunocorrection and Molecular ...(opens in a new tab)
    Tier 4Web · pmc.ncbi.nlm.nih.gov
  22. Understanding Thymalin Peptide: Mechanism, Benefits, and Optimal Usage(opens in a new tab)
    Tier 4Web · nbinno.com

See something wrong or out of date on this page? Report it.